Results 41 to 50 of about 33,699 (271)

Erratum: Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study [Corrigendum]. [PDF]

Int J Chron Obstruct Pulmon Dis
Charlie Strange, Joseph Tkacz, Jill Schinkel, Benjamin Lewing, Barnabie Agatep, Sean Swisher, Sushma Patel, Devechio Edwards, Daniel R. Touchette, Edward Portillo, Norbert Feigler, Michael Pollack   +11 more
europepmc   +3 more sources

Sustainable method development for the simultaneous detection of formoterol fumarate and glycopyrrolate [PDF]

Discover Chemistry
Jenee Christian, Bhanubhai N. Suhagia, Tejal Soni   +2 more
openalex   +2 more sources

Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study. [PDF]

EClinicalMedicine
Usmani OS, Martinez FJ, Pandya H, Camiolo M, Bednarczyk A, Kucz K, Kokot M, Gottfridsson C, Aurivillius M, Pettersson L, Mei J, Skansen K, Bell JL, Petullo D, Collison K, Bondarov P, Jassal M, Patel M.   +17 more
europepmc   +2 more sources

Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation. [PDF]

Respir Res, 2022
Suraya R, Nagano T, Ryanto GRT, Effendi WI, Hazama D, Katsurada N, Yamamoto M, Tachihara M, Emoto N, Nishimura Y, Kobayashi K.   +10 more
europepmc   +3 more sources

Glycopyrrolate and formoterol fumarate for the treatment of COPD [PDF]

Expert Review of Respiratory Medicine, 2020
Long acting bronchodilators are nowadays the central treatment for management of stable COPD. Several combinations exist within the market with different formulation devices. This article reviews a recent dual combination of glycopyrronium and formoterol fumarate in an innovative pMDI-fixed dual combination, Bevespi® Aerosphere.This article explored ...
Grillet, Pierre-Edouard, Le Souder, Cosette, Rohou, Juliette, Cazorla, Olivier, Charriot, Jérémy, Bourdin, Arnaud   +5 more
openaire   +3 more sources

Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts

Respiratory Research, 2021
Background In the Phase III KRONOS study, triple therapy with budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) was shown to reduce exacerbations and improve lung function versus glycopyrronium/formoterol fumarate dihydrate ...
Shigeo Muro, Hisatoshi Sugiura, Patrick Darken, Paul Dorinsky   +3 more
doaj   +1 more source

COMPARATIVE EFFICACY OF INHALED DRUGS FORMOTEROL / BECLOMETHASONE AND FORMOTEROL / BUDESONIDE AND BRONCHIAL ASTHMA

Архивъ внутренней медицины, 2016
There were examined 86 patients aged 20 to 65 years with a diagnosis of bronchial asthma (BA). The objective is to evaluate the level of disease control, to study the effectiveness, safety and usability when used Foster (beclomethasone dipropionate and ...
V. A. Nikitin, O. A. Lepuchova, L. V. Vasilieva, E. P. Karpuchina   +3 more
doaj   +1 more source

Rp-HPLC Method Development and Validation for The Quantification of Tiotropium Bromide and Formoterol Fumarate Dihydrate Rotacaps.

African Journal of Biomedical Research
D. O. Shah
openalex   +3 more sources

Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study [PDF]

, 2012
Introduction: The inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting beta2-agonist, formoterol fumarate (formoterol), have been combined in a single aerosol inhaler (fluticasone/formoterol).
Aalbers, René, Bodzenta-Lukaszyk, Anna, Brusselle, Guy, Grothe, Birgit, McIver, Tammy   +4 more
core   +1 more source

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD : a systematic review and meta-analysis [PDF]

, 2017
Acknowledgments The meta-analysis work was performed by Guruprasad Rao KS and Sharanbasappa Durg of Molecular Connections (P) Ltd, Bangalore, India, under the guidance of the manuscript authors and Novartis Pharma AG (Basel, Switzerland). Medical writing
Altman, Pablo, Anzueto, Antonio, Bader, Giovanni, Fogel, Robert, Kostikas, Konstantinos, Patalano, Francesco, Price, David B, Rodrigo, Gustavo J, Singh, Dave   +8 more
core   +2 more sources